The Alzheimer’s Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer’s disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Dallas P. Veitch,
Michael W. Weiner,
Melanie Miller,
Paul S. Aisen,
Miriam A. Ashford,
Laurel A. Beckett,
Robert C. Green,
Danielle Harvey,
Clifford R. Jack,
William Jagust,
Susan M. Landau,
John C. Morris,
Kwangsik T. Nho,
Rachel Nosheny,
Ozioma Okonkwo,
Richard J. Perrin,
Ronald C. Petersen,
Monica Rivera Mindt,
Andrew Saykin,
Leslie M. Shaw,
Arthur W. Toga,
Duygu Tosun,
for the Alzheimer’s Disease Neuroimaging Initiative | September 12, 2023

Wiley: Alzheimer’s & Dementia: Table of Contents